We believe that our data support the rational that CD8+ TILs infiltration and expression of PD-L1 are both required for the efficacy of checkpoint inhibitors targeting PD-1 or PD-L1 in lung cancer treated with immunotherapy in first or further line. The gene discussed is CD8A; the disease is lung cancer.